Pepaxto Adcom Saw Public Airing Of Unusual Level Of Discord Between US FDA, Oncopeptides

 
• By Sue Sutter
  
Thumbs up and down
The FDA and Oncopeptides seemed to agree on little at the recent ODAC meeting on Pepaxto. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers